Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161220 · ClinicalTrials.gov registry record · Phase 1
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
A Phase 1 study, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT06161220: Completed Phase 1 study, sponsored by Impax Laboratories.
NCT06161220 is a Phase 1 study that has completed, run by Impax Laboratories. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06161220, a Phase 1 study, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.
Primary Outcome
Change-from-baseline QTcF ( QTcF) will allow evaluation of the effects of carbidopa and moxifloxacin on cardiac repolarization based on model derived placebo-corrected ΔQTcF (ΔΔQTcF).
Interventions
- DRUG Placebo
- DRUG Carbidopa capsule
- DRUG Moxifloxacin Tablets, USP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2023-12-05 |
| Phase | Phase 1 |
What the finished NCT06161220 record still lists
NCT06161220 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06161220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06161220 about?
NCT06161220 is a clinical study titled "A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects". The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.
What is the current status of trial NCT06161220?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2023-10-30. Estimated completion is 2023-12-05.
What interventions are being tested in trial NCT06161220?
The interventions under investigation include: Placebo (DRUG), Carbidopa capsule (DRUG), Moxifloxacin Tablets, USP (DRUG).
Who is sponsoring clinical trial NCT06161220?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06161220's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI